{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:30:52Z","timestamp":1785871852185,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Angstrom Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ygyno.2012.03.023","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T07:37:20Z","timestamp":1332401840000},"page":"635-639","source":"Crossref","is-referenced-by-count":44,"title":["A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"125","author":[{"given":"Michael A.","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"De Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta A.","family":"Crispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.03.023_bb0005","series-title":"Cancer facts & figures 2011","author":"American Cancer Society","year":"2011"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0010","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1096\/fj.14.10.1400","article-title":"A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo","volume":"14","author":"Guo","year":"2000","journal-title":"FASEB J"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0015","first-page":"4678","article-title":"An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer","volume":"62","author":"Guo","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0020","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-11-0351","article-title":"A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation and inhibits the migration and metastasis of CD44-expressing cells","author":"Piotrowicz","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0002-9440(10)63855-2","article-title":"A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis","volume":"162","author":"Boyd","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0030","doi-asserted-by":"crossref","first-page":"8484","DOI":"10.1073\/pnas.150239497","article-title":"A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin","volume":"97","author":"Mishima","year":"2000","journal-title":"Proc Nat Acad Sci"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0035","author":"Sill","year":"2006","journal-title":"A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials, Technical Report 06-08, Department of Biostatistics, University at Buffalo"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2005.05.023","article-title":"A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial","volume":"99","author":"Berkenblit","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2008.06.028","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer","volume":"111","author":"Ghamande","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0055","first-page":"189","article-title":"CD44 cell adhesion molecules","volume":"52","author":"Goodison","year":"1999","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1097-2765(04)00080-2","article-title":"Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44","volume":"13","author":"Teriete","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0065","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1242\/jcs.045112","article-title":"Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions","volume":"123","author":"Schaller","year":"2010","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0070","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/MCB.14.3.1680","article-title":"Autophosphorylation of the focal adhesion kinase, pp 125FAK, directs SH2-dependent binding of pp60src","volume":"14","author":"Schaller","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0075","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/MCB.14.1.147","article-title":"Stable association of pp 60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK","volume":"14","author":"Cobb","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0080","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/372786a0","article-title":"Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase","volume":"372","author":"Schlaepfer","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1447-0756.2006.00422.x","article-title":"Significance of CD44v6 expression in gynecologic malignancies","volume":"32","author":"Hong","year":"2006","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2004.06.046","article-title":"Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity","volume":"95","author":"Bar","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0095","first-page":"5318","article-title":"CD44 expression indicates favorable prognosis in epithelial ovarian cancer","volume":"9","author":"Sillanpa","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00129039-200112000-00004","article-title":"Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas","volume":"9","author":"Afify","year":"2001","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0105","first-page":"1073","article-title":"Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival","volume":"5","author":"Kayastha","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0110","first-page":"3901","article-title":"Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases","volume":"19","author":"Schroder","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2559.1998.00347.x","article-title":"Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and over carcinomas","volume":"32","author":"Darai","year":"1998","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/MO:20:3:255","article-title":"The CD44 receptor is a molecular predictor of survival in ovarian cancer","volume":"20","author":"Rodriguez-Rodriguez","year":"2003","journal-title":"Med Oncol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1309\/KUK0-1M3D-LGNE-THXR","article-title":"Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas","volume":"116","author":"Ross","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ygyno.2012.03.023_bb0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/gyno.1998.5108","article-title":"CD44 splice variant expression in clear cell carcinoma of the ovary","volume":"71","author":"Rodriguez-Rodriguez","year":"1998","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200217X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200217X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T01:53:38Z","timestamp":1543110818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581200217X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S009082581200217X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.03.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}